Results 131 to 140 of about 3,492,883 (216)

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution' [PDF]

, 2017
No abstract ...
Daniel J Murphy, HG Colt, J Mazieres, JC Wan, JP Pignon, K Suzawa, Kevin G Blyth, L Calman, M Jamal-Hanjani, M Schuler, TD Crabtree, WC Hanna   +11 more
core   +1 more source

Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy

Brain Sciences
Background: Glioblastoma (GBM) is the most common and deadly type of brain cancer in adults. Dysregulation of receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR), contributes to therapeutic resistance. Drugs that inhibit tyrosine kinase activity and monoclonal antibodies against EGFR are strategies used in clinical ...
Karen Olthoff, Ayelén D. Nigra, Laura Natalia Milla Sanabria   +2 more
openaire   +4 more sources

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts

Oncology Reports, 2011
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for non-small cell lung cancer and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. On the other hand, it has been reported that a tumor continues to express epidermal growth factor receptor ...
IWAI, TOSHIKI, MORIYA, YOICHIRO, SHIRANE, MASATOSHI, FUJIMOTO-OUCHI, KAORI, MORI, KAZUSHIGE   +4 more
openaire   +3 more sources

Familial Adenomatous Polyposis—Risk of Cancer, Cancer Prevention, and Long‐Term Consequences: Learnings from Five Decades with the Danish Polyposis Register

APMIS, Volume 134, Issue 5, May 2026.
ABSTRACT Familial adenomatous polyposis (FAP) is a hereditary condition marked by the growth of hundreds to thousands of adenomatous polyps in the colon and rectum, significantly elevating the risk of colorectal cancer (CRC) if left untreated. Caused by pathogenic variants in the APC gene, FAP is typically identified in adolescence, often leading to ...
John Gásdal Karstensen
wiley   +1 more source

Repurposing metformin for cancer treatment: current clinical studies. [PDF]

, 2016
In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K, Arya, Ayush, Carneiro, Benedito, Chae, Young Kwang, Chandra, Sunandana, Giles, Francis, Kalyan, Aparna, Kaplan, Jason, Malecek, Mary-Kate, Platanias, Leonidas, Shin, Daniel Sanghoon   +10 more
core   +1 more source

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

PLoS Medicine, 2005
Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be ...
William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus   +9 more
openaire   +4 more sources

Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Lung cancer continues to be the leading cause of morbidity and mortality associated with malignancies. Identifying prognostic factors is vital for improving survival outcomes. This study assessed the impact of clinical, demographic, and genetic factors on overall survival (OS) and progression‐free survival (PFS) in patients with non‐small cell
Gayathri Baburaj, Ananth Pai, Varun Kumar Sudha Gururaj, Satyanarayana Poojari, Mahadev Rao, Karthik S. Udupa   +5 more
wiley   +1 more source

Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer [PDF]

, 2018
Non-small cell lung cancer (NSCLC) is currently the number one cause of cancer death in the United States for both men and women.1 Mutations in the epidermal growth factor receptor (EGFR) gene are detected in approximately 30% of individuals with ...
Omerza, PhD, Gregory, Schoenberg, Benjamen   +1 more
core   +1 more source

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]

, 2018
Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James, Dhar, Manjima, Di Carlo, Dino, Elashoff, David, Garon, Edward B, Goldman, Jonathan W, Grogan, Tristan, Kulkarni, Rajan P, Matsumoto, Melissa, Sollier Christen, Elodie, Wong, Jessica   +10 more
core   +3 more sources